Pembrolizumab for BCG-unresponsive high-risk NMIBC: Considerations for use

Video

Arjun V. Balar, MD, walks through the patient discussion when weighing the use of pembrolizumab (Keytruda).

In this video, Arjun V. Balar, MD, explains what a urologist should look for or consider regarding tumor and patient characteristics when deciding on use of pembrolizumab in patients with BCG-unresponsive, high-risk non–muscle invasive bladder cancer. Balar is associate professor of medicine at the NYU Grossman School of Medicine and genitourinary medical oncology program director at NYU Langone’s Perlmutter Cancer Center, New York.

Related Videos
Dr. Jasmeet Kaur in an interview with Urology Times
Dr. Martin Voss in an interview with Urology Times
Dr. Jacqueline Brown in an interview with Urology Times
blurred clinic hallway
Dr. Dalia Kaakour in an interview with red Urology Times backdrop
Dr. Maria Teresa Bourlon in an interview with Urology Times
Dr. David Braun in an interview with Urology Times
Dr. Neeraj Agarwal in an interview with Urology Times
Dr. Saby George in an interview with Urology Times
Dr. Laura Bukavina in an interview with Urology Times
Related Content
© 2024 MJH Life Sciences

All rights reserved.